China (Mainland)
Imatinib CAS No. 152459-95-5 Used for Antineoplastic Agents CAS NO.152459-95-5
- Min.Order: 0 Gram
- Payment Terms: L/C
- Product Details
Keywords
- 152459-95-5
- 152459-95-5
- 152459-95-5
Quick Details
- ProName: Imatinib CAS No. 152459-95-5 Used for ...
- CasNo: 152459-95-5
- Molecular Formula: C29H31N7O
- Appearance: white crystalline powder
- Application: use in chemical
- DeliveryTime: within a week
- PackAge: bags
- Port: Shanghai
- ProductionCapacity: 12 Kilogram/Day
- Purity: 99%
- Storage: Kept in a well-closed, light-resistant...
- Transportation: by sea or express
- LimitNum: 0 Gram
- Moisture Content: 0.1%
- Impurity: 0.05%
- Water content: 0%
Superiority
Details
Imatinib CAS No. 152459-95-5 Used for Antineoplastic Agents
Quick Details
- CAS No.: 152459-95-5
- Other Names: IMA-3
- MF: C29H31N7O
- EINECS No.: 152459-95-5
- Place of Origin: Shanghai, China (Mainland)
- Type: Antineoplastic Agents
- Grade Standard: Medicine Grade
- Usage: Animal Pharmaceuticals
- Brand Name: TwoChem
- Model Number: 152459-95-5
- Purity: 99%
- Appearance: Orange powder
- Application: Pharmaceutical intermediates
-
Introduction
Imatinib is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.